buy side building, page-55

http://www.morgans.com.au/Blog/2013/November/Five-life-science-stocks-for-Christmas.aspx


and just a reminder from the rbs report

"ACL recently released two key
short-term catalysts (within 3 to 6
months) of a potential partnership
deal for HA-Irinotecan and the
potential to monetise the
fondaparinux revenue stream (which
delivered revenue of A$10m in FY13).
If ACL is able to achieve either or
both these milestones the share price
will re-rate quickly though our price
target"

http://www.alchemia.com.au/Portals/0/ACL131101_Gaining%20traction%20in%20US%20market.pdf